CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ANKRD10-IT1 (ImmuneEditome ID:100505494)

1. Gene summary of enriched editing regions for ANKRD10-IT1

check button Gene summary
Gene informationGene symbol

ANKRD10-IT1

Gene ID

100505494

GeneSynonyms-
GeneCytomap

13q34

GeneTypencRNA
GeneDescriptionANKRD10 intronic transcript 1 (non-protein coding)
GeneModificationdate20220125
UniprotID.
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr13:110895316-110895466:-ENST00000426991.2ENSG00000229152.2ANKRD10-IT1ncRNA_exonicAluSx3chr13:110895316-110895466:-.alignment
chr13:110897230-110897423:-ENST00000426991.2ENSG00000229152.2ANKRD10-IT1ncRNA_intronicL1MA5,AluJrchr13:110897230-110897423:-.alignment
chr13:110898638-110900091:-ENST00000426991.2ENSG00000229152.2ANKRD10-IT1ncRNA_exonicAluJr,AluJb,AluSq2chr13:110898638-110900091:-.alignment


Top

2. Tumor-specific enriched editing regions for ANKRD10-IT1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000229152.2,ANKRD10-IT1LUSCEAG7.1008e-03image
chr13:110898638-110900091:-STADEER1.9378e-02image
ENSG00000229152.2,ANKRD10-IT1STADEAG1.7805e-02image
chr13:110898638-110900091:-THCAEER4.4333e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr13:110895316-110895466:-KIRPPathEER4.3983e-026.8009e-030.2818image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr13:110898638-110900091:-KIRPEER4.9902e-022.3038e-021.1592e+05image
ENSG00000229152.2,ANKRD10-IT1KIRPEAG1.3278e-034.1331e-041.1020e+07image
ENSG00000229152.2,ANKRD10-IT1OVEAG3.5266e-021.9870e-021.5528e+01image

Top

3. Enriched editing regions and immune related genes for ANKRD10-IT1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr13:110898638-110900091:-OVEERENSG00000229152,ANKRD10-IT1-0.43198.1249e-103.4257e-13-0.4216imageNADAR;CSTF2T;EIF4A3;ELAVL1;HNRNPA2B1;PTBP1;TARDBP;U2AF2NAMacrophages_M0GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

More results



Top

4. Enriched editing regions and immune related splicing for ANKRD10-IT1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr13:110898638-110900091:-
KIRCEERIRENSG00000087087.14chr7100882052:100882241:100882764:100883090-0.19981.0597e-021.2341e-10-0.4071imageNADAR;CSTF2T;EIF4A3;ELAVL1;HNRNPA2B1;PTBP1;TARDBP;U2AF2NAMacrophages_M2GSVA_HALLMARK_HYPOXIA
ENSG00000229152.2,ANKRD10-IT1
OVEAGIRENSG00000181085.10chr8143716339:143720287:143720702:143720840-0.39724.8525e-086.0710e-13-0.4240imageNAIFM1;CSTF2T;DDX42;DGCR8;EIF4A3;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP2;ILF3;KHDRBS1;LIN28;LIN28B;MOV10;NOP56;NUMA1;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SLTM;SND1;SRSF1;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2NAT_cells_CD8GSVA_HALLMARK_ADIPOGENESIS
ENSG00000229152.2,ANKRD10-IT1
OVEAGIRENSG00000143224.13chr1161167609:161168127:161168431:161168545-0.40154.9636e-084.7476e-13-0.4229imageNACIN1;AIFM1;AUH;CNBP;CSTF2T;DDX42;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LARP7;LIN28;LIN28B;MSI2;NOP56;NOP58;NPM1;NUMA1;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SLBP;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2;YWHAGNANK_cells_restingGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000229152.2,ANKRD10-IT1
OVEAGIRENSG00000168397.12chr2241670725:241671405:241672190:241672381-0.43073.5817e-091.6770e-12-0.4088imageNACIN1;ADAR;AIFM1;AUH;CELF2;CNBP;CSTF2T;DDX42;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;LARP7;LIN28;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SLBP;SLTM;SND1;SRSF1;SRSF10;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2;YTHDC1;YWHAGNAMacrophages_M0GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000229152.2,ANKRD10-IT1
OVEAGIRENSG00000148824.14chr10133399528:133399653:133401528:133401847-0.35771.2126e-065.0652e-12-0.4132imageNACIN1;ADAR;AIFM1;AUH;CELF2;CNBP;CSTF2T;DDX42;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;LARP7;LIN28;LIN28B;MOV10;MSI2;NOP56;NOP58;NPM1;NUMA1;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2;YWHAG;ZC3H7BNANK_cells_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
ENSG00000229152.2,ANKRD10-IT1
OVEAGIRENSG00000154222.10chr152352531:52353223:52353517:52353647-0.43293.5868e-092.5367e-13-0.4223imageNACIN1;ADAR;AIFM1;AUH;CELF2;CNBP;CSTF2T;DDX42;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;LIN28;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2;YTHDC1;YWHAGNAT_cells_CD8GSVA_HALLMARK_ADIPOGENESIS
ENSG00000229152.2,ANKRD10-IT1
OVEAGIRENSG00000261884.2chr1667934796:67934948:67935295:67935478-0.36545.0590e-085.7403e-12-0.4355imageNADAR;AIFM1;AUH;CNBP;CSTF2T;DDX54;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28B;MOV10;MSI2;NOP56;NOP58;PCBP2;RANGAP1;RBFOX2;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TROVE2;U2AF2;UPF1;XRN2;YWHAGNAT_cells_CD8GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000229152.2,ANKRD10-IT1
OVEAGIRENSG00000105875.9chr7135186971:135187169:135188432:135188545-0.46982.8363e-111.2081e-13-0.4318imageNADAR;CELF2;CNBP;CSTF2T;DDX42;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28;LIN28B;MOV10;NOP56;NOP58;NUMA1;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2NAMacrophages_M1GSVA_HALLMARK_FATTY_ACID_METABOLISM
ENSG00000229152.2,ANKRD10-IT1
OVEAGIRENSG00000126456.11chr1949664673:49664846:49665630:49665705-0.47632.8363e-111.1922e-16-0.4741imageNACIN1;ADAR;AIFM1;AUH;CELF2;CNBP;CSTF2T;DDX42;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LARP7;LIN28;LIN28B;MOV10;MSI2;NOP56;NOP58;NPM1;NUMA1;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2;YTHDC1;YWHAGIRF3T_cells_CD8GSVA_HALLMARK_GLYCOLYSIS
ENSG00000229152.2,ANKRD10-IT1
OVEAGIRENSG00000110455.9chr1144075525:44078784:44079530:44079607-0.38605.4821e-087.2064e-12-0.4120imageNAIFM1;CNBP;CSTF2T;DDX42;DDX54;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;ILF3;KHDRBS1;LARP7;LIN28B;MSI2;NOP56;NOP58;NUMA1;PTBP1;RBFOX2;SAFB2;SLTM;SND1;SRSF1;SRSF10;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2;YTHDC1;YWHAGNAMacrophages_M1GSVA_HALLMARK_FATTY_ACID_METABOLISM

More results



Top

5. Enriched editing regions and immune infiltration for ANKRD10-IT1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr13:110898638-110900091:-BLCAEERNK_cells_activated6.0247e-030.1991image
ENSG00000229152.2,ANKRD10-IT1BLCAEAGNK_cells_activated9.0787e-040.2197image
chr13:110897230-110897423:-BRCAEERT_cells_regulatory_(Tregs)4.0221e-030.1246image
chr13:110898638-110900091:-BRCAEERT_cells_regulatory_(Tregs)1.4639e-070.1759image
ENSG00000229152.2,ANKRD10-IT1BRCAEAGDendritic_cells_resting2.5508e-03-0.0988image
ENSG00000229152.2,ANKRD10-IT1CESCEAGT_cells_CD82.4678e-020.1728image
chr13:110898638-110900091:-CHOLEERNK_cells_activated4.0016e-020.4408image
chr13:110898638-110900091:-COADEERNK_cells_activated7.9977e-030.1894image
ENSG00000229152.2,ANKRD10-IT1COADEAGMacrophages_M02.4351e-02-0.1546image
chr13:110898638-110900091:-ESCAEERMacrophages_M13.5605e-030.2292image
ENSG00000229152.2,ANKRD10-IT1ESCAEAGB_cells_naive9.8370e-03-0.2029image
chr13:110898638-110900091:-GBMEERPlasma_cells3.2739e-030.3019image
ENSG00000229152.2,ANKRD10-IT1GBMEAGEosinophils4.4189e-020.1897image
chr13:110898638-110900091:-HNSCEERT_cells_CD81.7307e-020.2197image
chr13:110898638-110900091:-KIRCEERT_cells_CD4_memory_activated4.6798e-020.1189image
ENSG00000229152.2,ANKRD10-IT1KIRCEAGMast_cells_activated5.3402e-03-0.1652image
chr13:110898638-110900091:-LAMLEERDendritic_cells_activated2.0072e-020.1903image
ENSG00000229152.2,ANKRD10-IT1LAMLEAGT_cells_follicular_helper4.4515e-020.1660image
chr13:110898638-110900091:-LGGEERPlasma_cells1.4258e-020.1263image
ENSG00000229152.2,ANKRD10-IT1LGGEAGMast_cells_activated3.6729e-02-0.1009image
chr13:110898638-110900091:-LIHCEERT_cells_CD4_memory_activated3.8046e-020.2663image
ENSG00000229152.2,ANKRD10-IT1LUADEAGNK_cells_activated6.3998e-03-0.1377image
chr13:110898638-110900091:-LUSCEERMacrophages_M22.6883e-020.1426image
ENSG00000229152.2,ANKRD10-IT1LUSCEAGT_cells_CD82.8365e-03-0.1787image
ENSG00000229152.2,ANKRD10-IT1MESOEAGMonocytes2.3907e-020.3129image
chr13:110898638-110900091:-OVEERT_cells_CD81.0317e-060.2906image
ENSG00000229152.2,ANKRD10-IT1OVEAGT_cells_CD81.2243e-060.2877image
chr13:110898638-110900091:-PAADEERNeutrophils1.4300e-020.1997image
ENSG00000229152.2,ANKRD10-IT1PAADEAGT_cells_gamma_delta7.4236e-030.2136image
chr13:110898638-110900091:-PCPGEERDendritic_cells_activated8.0879e-040.4278image
chr13:110898638-110900091:-PRADEERMacrophages_M23.6998e-020.1088image
ENSG00000229152.2,ANKRD10-IT1PRADEAGMacrophages_M21.5982e-020.1212image
chr13:110898638-110900091:-SARCEERMonocytes8.2685e-030.2681image
chr13:110898638-110900091:-SKCMEERT_cells_follicular_helper1.0484e-020.1567image
ENSG00000229152.2,ANKRD10-IT1SKCMEAGDendritic_cells_resting6.9285e-040.1926image
chr13:110898638-110900091:-STADEERMacrophages_M28.1092e-040.1746image
ENSG00000229152.2,ANKRD10-IT1STADEAGB_cells_naive5.4229e-03-0.1447image
chr13:110898638-110900091:-THCAEERNK_cells_resting1.9374e-02-0.1309image
ENSG00000229152.2,ANKRD10-IT1THYMEAGT_cells_gamma_delta4.3990e-040.4431image
chr13:110898638-110900091:-UCECEERT_cells_follicular_helper5.5587e-030.2966image
chr13:110898638-110900091:-UCSEERNeutrophils2.4023e-030.5901image
ENSG00000229152.2,ANKRD10-IT1UCSEAGDendritic_cells_activated1.9101e-030.5277image
ENSG00000229152.2,ANKRD10-IT1UVMEAGB_cells_memory2.5059e-020.4562image


Top

6. Enriched editing regions and immune gene sets for ANKRD10-IT1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000229152.2,ANKRD10-IT1BLCAEAG3.8899e-030.19174.5370e-020.13364.2116e-040.23322.5623e-030.2001image
ENSG00000229152.2,ANKRD10-IT1STADEAG2.8737e-050.21621.4511e-020.12735.3764e-030.14484.2096e-050.2118image
chr13:110898638-110900091:-STADEER8.1260e-040.17451.1452e-020.13222.0610e-020.12111.2926e-060.2502image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr13:110898638-110900091:-BLCAGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER1.0283e-060.3466image
ENSG00000229152.2,ANKRD10-IT1BLCAGSVA_HALLMARK_GLYCOLYSISEAG7.8500e-050.2602image
chr13:110897230-110897423:-BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER5.4688e-070.2153image
chr13:110898638-110900091:-BRCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER4.7970e-110.2191image
ENSG00000229152.2,ANKRD10-IT1BRCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.2252e-090.1945image
ENSG00000229152.2,ANKRD10-IT1CESCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG1.2839e-030.2457image
chr13:110898638-110900091:-CESCGSVA_HALLMARK_HEME_METABOLISMEER2.5670e-040.3120image
ENSG00000229152.2,ANKRD10-IT1CHOLGSVA_HALLMARK_DNA_REPAIREAG4.1333e-020.3880image
chr13:110898638-110900091:-COADGSVA_HALLMARK_IL2_STAT5_SIGNALINGEER1.3007e-020.1776image
ENSG00000229152.2,ANKRD10-IT1COADGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG6.9798e-030.1848image
ENSG00000229152.2,ANKRD10-IT1DLBCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.3743e-030.5101image
chr13:110898638-110900091:-DLBCGSVA_HALLMARK_KRAS_SIGNALING_DNEER4.6947e-020.3656image
ENSG00000229152.2,ANKRD10-IT1ESCAGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.7818e-040.2912image
chr13:110898638-110900091:-ESCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.0536e-050.3405image
chr13:110898638-110900091:-GBMGSVA_HALLMARK_HEME_METABOLISMEER2.0837e-020.2394image
ENSG00000229152.2,ANKRD10-IT1GBMGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG2.8874e-030.2778image
ENSG00000229152.2,ANKRD10-IT1HNSCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG3.1637e-020.1916image
chr13:110898638-110900091:-HNSCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER4.7372e-02-0.1837image
chr13:110898638-110900091:-KIRCGSVA_HALLMARK_COAGULATIONEER2.0824e-060.2792image
ENSG00000229152.2,ANKRD10-IT1KIRCGSVA_HALLMARK_UV_RESPONSE_UPEAG8.8738e-050.2309image
ENSG00000229152.2,ANKRD10-IT1KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG4.8114e-030.2246image
chr13:110895316-110895466:-KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER4.1590e-040.3414image
chr13:110898638-110900091:-KIRPGSVA_HALLMARK_KRAS_SIGNALING_DNEER3.7745e-020.1784image
chr13:110898638-110900091:-LAMLGSVA_HALLMARK_ANGIOGENESISEER1.3886e-020.2012image
chr13:110898638-110900091:-LGGGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.8168e-050.2191image
ENSG00000229152.2,ANKRD10-IT1LGGGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG8.7115e-100.2905image
ENSG00000229152.2,ANKRD10-IT1LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEAG9.2551e-03-0.2986image
chr13:110898638-110900091:-LUADGSVA_HALLMARK_PEROXISOMEEER4.7467e-030.1451image
ENSG00000229152.2,ANKRD10-IT1LUADGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.7430e-050.2154image
chr13:110898638-110900091:-LUSCGSVA_HALLMARK_PROTEIN_SECRETIONEER8.1382e-040.2143image
ENSG00000229152.2,ANKRD10-IT1LUSCGSVA_HALLMARK_HEME_METABOLISMEAG7.8658e-050.2350image
chr13:110898638-110900091:-MESOGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.4194e-020.3758image
chr13:110898638-110900091:-OVGSVA_HALLMARK_BILE_ACID_METABOLISMEER3.3433e-080.3265image
ENSG00000229152.2,ANKRD10-IT1OVGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG8.4516e-100.3592image
ENSG00000229152.2,ANKRD10-IT1PAADGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG7.3763e-030.2138image
chr13:110898638-110900091:-PAADGSVA_HALLMARK_KRAS_SIGNALING_DNEER6.0371e-030.2232image
ENSG00000229152.2,ANKRD10-IT1PCPGGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG1.0521e-030.3596image
chr13:110898638-110900091:-PCPGGSVA_HALLMARK_KRAS_SIGNALING_DNEER5.0061e-03-0.3637image
ENSG00000229152.2,ANKRD10-IT1PRADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG9.8497e-040.1652image
chr13:110898638-110900091:-PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.8556e-040.1937image
ENSG00000229152.2,ANKRD10-IT1READGSVA_HALLMARK_DNA_REPAIREAG4.8183e-030.3332image
chr13:110898638-110900091:-READGSVA_HALLMARK_SPERMATOGENESISEER3.4666e-030.3657image
chr13:110898638-110900091:-SARCGSVA_HALLMARK_NOTCH_SIGNALINGEER1.9520e-020.2380image
ENSG00000229152.2,ANKRD10-IT1SARCGSVA_HALLMARK_APICAL_SURFACEEAG1.1726e-020.2333image
chr13:110898638-110900091:-SKCMGSVA_HALLMARK_KRAS_SIGNALING_DNEER8.6814e-030.1606image
ENSG00000229152.2,ANKRD10-IT1SKCMGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.8489e-040.2118image
chr13:110898638-110900091:-STADGSVA_HALLMARK_UV_RESPONSE_UPEER1.6319e-100.3265image
ENSG00000229152.2,ANKRD10-IT1STADGSVA_HALLMARK_UV_RESPONSE_UPEAG2.2155e-080.2865image
chr13:110898638-110900091:-TGCTGSVA_HALLMARK_ANGIOGENESISEER2.8024e-03-0.3793image
chr13:110898638-110900091:-THCAGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.2952e-040.2127image
ENSG00000229152.2,ANKRD10-IT1THCAGSVA_HALLMARK_GLYCOLYSISEAG3.4442e-060.2442image
ENSG00000229152.2,ANKRD10-IT1THYMGSVA_HALLMARK_ADIPOGENESISEAG1.2359e-030.4106image
chr13:110898638-110900091:-THYMGSVA_HALLMARK_ADIPOGENESISEER8.9858e-030.3771image
chr13:110898638-110900091:-UCECGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER6.6106e-030.2908image
ENSG00000229152.2,ANKRD10-IT1UCECGSVA_HALLMARK_UV_RESPONSE_UPEAG5.3435e-050.3645image
chr13:110898638-110900091:-UCSGSVA_HALLMARK_NOTCH_SIGNALINGEER3.6786e-03-0.5694image
ENSG00000229152.2,ANKRD10-IT1UCSGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.6666e-02-0.4201image


Top

7. Enriched editing regions and drugs for ANKRD10-IT1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000229152.2,ANKRD10-IT1BLCAAxitinibEAG1.1226e-040.2547image
chr13:110898638-110900091:-BLCAAxitinibEER2.5405e-040.2631image
chr13:110897230-110897423:-BRCAImatinibEER1.3164e-030.1391image
chr13:110898638-110900091:-BRCAABT.263EER3.3872e-070.1710image
ENSG00000229152.2,ANKRD10-IT1BRCACHIR.99021EAG6.1318e-060.1477image
chr13:110898638-110900091:-CESCATRAEER5.8257e-04-0.2944image
ENSG00000229152.2,ANKRD10-IT1CESCCHIR.99021EAG3.4565e-030.2237image
chr13:110898638-110900091:-CHOLDoxorubicinEER2.8837e-03-0.6045image
ENSG00000229152.2,ANKRD10-IT1COADBMS.708163EAG2.5331e-03-0.2064image
chr13:110898638-110900091:-COADElesclomolEER2.1593e-03-0.2184image
chr13:110898638-110900091:-DLBCJW.7.52.1EER3.6545e-030.5142image
ENSG00000229152.2,ANKRD10-IT1DLBCAMG.706EAG4.7289e-03-0.4941image
chr13:110898638-110900091:-ESCAKIN001.135EER2.2530e-05-0.3283image
ENSG00000229152.2,ANKRD10-IT1ESCAKIN001.135EAG1.1823e-05-0.3377image
chr13:110898638-110900091:-GBMCytarabineEER9.2981e-030.2684image
ENSG00000229152.2,ANKRD10-IT1GBMBAY.61.3606EAG6.3765e-030.2552image
chr13:110898638-110900091:-HNSCBleomycinEER8.4268e-03-0.2425image
ENSG00000229152.2,ANKRD10-IT1HNSCGefitinibEAG3.3873e-02-0.1915image
chr13:110898638-110900091:-KIRCBMS.536924EER5.6396e-06-0.2680image
ENSG00000229152.2,ANKRD10-IT1KIRCBMS.536924EAG1.3067e-04-0.2262image
chr13:110898638-110900091:-KIRPJW.7.52.1EER4.1943e-020.1747image
ENSG00000229152.2,ANKRD10-IT1KIRPCGP.60474EAG2.7618e-02-0.1764image
chr13:110895316-110895466:-KIRPAZD6482EER8.2603e-050.3780image
chr13:110898638-110900091:-LAMLKIN001.135EER4.4993e-03-0.2315image
ENSG00000229152.2,ANKRD10-IT1LAMLKU.55933EAG4.5207e-02-0.1654image
chr13:110898638-110900091:-LGGCCT007093EER9.2746e-04-0.1701image
ENSG00000229152.2,ANKRD10-IT1LGGAP.24534EAG5.3670e-050.1937image
ENSG00000229152.2,ANKRD10-IT1LIHCAS601245EAG8.9972e-040.3756image
ENSG00000229152.2,ANKRD10-IT1LUADABT.888EAG3.4883e-030.1474image
chr13:110898638-110900091:-LUSCKU.55933EER1.2460e-020.1608image
ENSG00000229152.2,ANKRD10-IT1LUSCGW843682XEAG2.1822e-020.1378image
ENSG00000229152.2,ANKRD10-IT1MESOJNJ.26854165EAG4.8168e-020.2754image
chr13:110898638-110900091:-MESOAUY922EER1.4486e-020.3747image
ENSG00000229152.2,ANKRD10-IT1OVBMS.509744EAG1.7235e-08-0.3318image
chr13:110898638-110900091:-OVBMS.509744EER4.3179e-05-0.2449image
ENSG00000229152.2,ANKRD10-IT1PAADBleomycinEAG1.3083e-060.3761image
chr13:110898638-110900091:-PAADKU.55933EER5.9250e-04-0.2791image
chr13:110898638-110900091:-PCPGJNJ.26854165EER1.7026e-020.3122image
ENSG00000229152.2,ANKRD10-IT1PCPGBMS.754807EAG4.0827e-02-0.2292image
ENSG00000229152.2,ANKRD10-IT1PRADBIRB.0796EAG5.6747e-040.1727image
chr13:110898638-110900091:-PRADCEP.701EER3.3149e-040.1861image
ENSG00000229152.2,ANKRD10-IT1READCCT007093EAG4.4304e-020.2412image
chr13:110898638-110900091:-READAZD6244EER2.4053e-020.2864image
ENSG00000229152.2,ANKRD10-IT1SARCBryostatin.1EAG6.3651e-03-0.2520image
chr13:110898638-110900091:-SARCBI.2536EER2.0460e-030.3109image
ENSG00000229152.2,ANKRD10-IT1SKCMJNJ.26854165EAG9.2754e-03-0.1483image
chr13:110898638-110900091:-SKCMCamptothecinEER1.0304e-020.1571image
chr13:110898638-110900091:-STADBortezomibEER1.4785e-03-0.1658image
ENSG00000229152.2,ANKRD10-IT1STADLFM.A13EAG1.8335e-030.1619image
ENSG00000229152.2,ANKRD10-IT1TGCTBosutinibEAG1.6935e-02-0.2826image
chr13:110898638-110900091:-TGCTCHIR.99021EER5.3582e-030.3552image
chr13:110898638-110900091:-THCABIBW2992EER1.0294e-04-0.2157image
ENSG00000229152.2,ANKRD10-IT1THCACCT007093EAG4.2471e-030.1518image
ENSG00000229152.2,ANKRD10-IT1THYMAZD.0530EAG1.6779e-020.3103image
chr13:110898638-110900091:-THYMDasatinibEER3.7700e-020.3074image
chr13:110898638-110900091:-UCECCMKEER9.0445e-030.2799image
ENSG00000229152.2,ANKRD10-IT1UCECGDC0941EAG4.8312e-030.2589image
chr13:110898638-110900091:-UCSAP.24534EER3.2035e-020.4386image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType